SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
SRRK

Scholar Rock Holding Corp (SRRK)

NASDAQ: SRRK · USD
Healthcare · Biotechnology
$48.13-$2.24 (-4.45%)
 
Market cap
$5.87B
Insider Score
Analyst consensus
Market Cap$5.87B+26.6%
Revenue (ttm)$570.00K
Net Income-$413.61M
EPS-$3.23
Shares Out122.00M
PE Ration/a
Forward PE-20.08
Dividendn/a
Ex-Dividend Daten/a
Volume2,076,204
Open$49.63
Previous Close$50.37
Day's Range$47.94 - $52.17
52-Week Range$38.69 - $61.76
Beta0.79
AnalystsStrong Buy
Price Target$70.06(+45.57%)
Earnings DateNov 10, 2026

About SRRK

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on improving the lives of children and adults with spinal muscular atrophy (SMA) and other rare, severe, and debilitating neuromuscular diseases. The company's novel understanding of the molecular mechanisms of growth factor activation within the transforming growth factor beta (TGFß) superfamily has enabled the development of a proprietary platform. This platform is used for the development of monoclonal antibodies that locally and selectively target the precursor, or latent, forms of growth factors. The company is developing Apitegromab, an inhibitor of the activation of myostatin, which is in a Phase 2 clinical trial for the treatment of SMA and facioscapulohumeral muscular dystrophy (FSHD). Additionally, SRK-439, an anti-pro/latent myostatin antibody, is in a Phase 1 clinical trial for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. SRK-181 is a Phase 2-ready investigational inhibitor of latent TGFß1 for the treatment of patients with solid tumors that are resistant to anti-PD-(L)1 antibody therapies. The company also offers products in pre-clinical development, including SRK-373, a selective inhibitor of the latent TGFß1 isoform with selective activity in the fibrotic extracellular matrix, for the treatment of fibrotic diseases, and SRK-256, an inhibitor of RGMc, or hemojuvelin, for the treatment of iron-restricted anemias. Scholar Rock Holding Corporation is also developing a pipeline that includes programs for the treatment of patients with rare, severe, and debilitating neuromuscular diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.

Address
301 Binney Street, Cambridge, MA, 02142, United States
Market Cap
5.87 billion
Employees
289
Industrial Classification
Biotechnology

Scholar Rock Holding Corp Stock Analysis — InsiderScore

Insider Score
See top-rated InsiderScore stocks ›
28th Percentile Overall Score
SRRK InsiderScore:59 / 99

Scholar Rock Holding Corp scored higher than 28% of companies evaluated by InsiderBuying, and ranked 58th out of 103 stocks in the biotech sector.

Scores are percentile-ranked against every company we scored that day, with extra weight given to the size and conviction of each purchase and the seniority of the buyer.

Dollars Committed

Insiders at Scholar Rock Holding Corp bought $12.00 million of stock across 6 purchases in the last 90 days, the largest of them $4.08 million.

Stake Increase

The average purchase added about 6% to the buyer's existing holding. Doubling a stake earns full marks here; topping up an already large position earns very little.

New Positions

Every buyer already held stock, so each purchase is an increase rather than a first position.

This category carries 35% of the Insider Score.

What Are Insiders Doing?

Open-market buy / sell balanceNet Buying
Sold
$923.08K
Bought
$12.00M

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
10 Buy2 Hold0 SellAvg target $65.57 (+36.2%)

12 firms rating SRRK in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-4.45%
5 Days
+11.40%
1 Month
+14.70%
6 Months
+0.00%
1 Year
+26.59%

$SRRK stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in SRRK holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by SRRK's directors and management

Net Shares Purchased by Insiders−300k−150k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

SRRK Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New SRRK patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to SRRK from public contracts

Source: USAspending.gov

Bull Case vs Bear Case

AI-generated from SRRK’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
40.58
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
62

News check: Q3 revenue beats and narrowing losses offset by pre-bell share decline; mixed but operationally constructive news around iSemble launch.

Recent Insider Activity

Buys
6
Sells
13
Buy Value
$12.00M
Distinct Buyers
1

Insider Score Trend Over Time

-9.0 since Oct 30
0255075100Oct 30 — Insider Score 65.3Oct 31 — Insider Score 65.3Nov 1 — Insider Score 65.3Nov 2 — Insider Score 65.3Nov 3 — Insider Score 65.0Nov 4 — Insider Score 64.7Nov 5 — Insider Score 64.3Nov 6 — Insider Score 64.0Nov 7 — Insider Score 63.7Nov 8 — Insider Score 63.8Nov 9 — Insider Score 63.8Nov 10 — Insider Score 63.4Nov 11 — Insider Score 62.9Nov 12 — Insider Score 62.4Nov 13 — Insider Score 61.8Nov 14 — Insider Score 61.2Nov 15 — Insider Score 61.2Nov 16 — Insider Score 60.9Nov 17 — Insider Score 60.2Nov 18 — Insider Score 58.8Nov 19 — Insider Score 57.7Nov 20 — Insider Score 56.1Nov 21 — Insider Score 56.1Nov 22 — Insider Score 56.3Oct 30Nov 10Nov 22

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

IBRNiShares Neuroscience and Healthcare ETF3.65%
MNTLTema Neuroscience And Mental Health ETF1.71%
TDNAT. Rowe Price Biotech ETF1.58%
GURUGlobal X - Guru Index ETF1.25%
XBIState Street SPDR S&P Biotech ETF0.80%
BBCVirtus Biotech Clinical Trials ETF0.78%
SGRWHarbor Active Small Cap Growth ETF (SGRW)0.75%
PCSGPolen 5Perspectives Small-Mid Growth ETF0.58%
MMSCFirst Trust Multi-Manager Small Cap Opportunities ETF0.50%
HRTSTema Heart & Health ETF0.46%
ACSGAmerican Century Small Cap Growth Insights ETF0.45%
IBBQInvesco Nasdaq Biotechnology ETF0.34%

Weight is the stock’s share of each fund’s holdings.